The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Noninvasive Urinary Metabolomic Profiling Identifies Diagnostic and Prognostic Markers in Lung Cancer
Open accessAbstract
Lung cancer remains the most common cause of cancer deaths worldwide, yet there is currently a lack of diagnostic noninvasive biomarkers that could guide treatment decisions. Small molecules (<1,500 Da) were measured in urine collected from 469 patients with lung cancer and 536 population controls using unbiased liquid chromatography/mass spectrometry. Clinical putative diagnostic and prognostic biomarkers were validated by quantitation and normalized to creatinine levels at two different time points and further confirmed in an independent sample set, which comprises 80 cases and 78 population controls, with similar demographic and clinical characteristics when compared with the training set. Creatine riboside (IUPAC name: 2-{2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-oxolan-2-yl]-1-methylcarbamimidamido}acetic acid), a novel molecule identified in this study, and N-acetylneuraminic acid (NANA) were each significantly (P < 0.00001) elevated in non–small cell lung cancer and associated with worse prognosis [HR = 1.81 (P = 0.0002), and 1.54 (P = 0.025), respectively]. Creatine riboside was the strongest classifier of lung cancer status in all and stage I-II cases, important for early detection, and also associated with worse prognosis in stage I-II lung cancer (HR = 1.71, P = 0.048). All measurements were highly reproducible with intraclass correlation coefficients ranging from 0.82 to 0.99. Both metabolites were significantly (P < 0.03) enriched in tumor tissue compared with adjacent nontumor tissue (N = 48), thus revealing their direct association with tumor metabolism. Creatine riboside and NANA may be robust urinary clinical metabolomic markers that are elevated in tumor tissue and associated with early lung cancer diagnosis and worse prognosis. Cancer Res; 74(12); 3259–70. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Reduced Cortisol Metabolism during Critical Illness
Boonen, E., Vervenne, H., Meersseman, P., Andrew, R., Mortier, L., Declercq, P. E., Vanwijngaerden, Y.-M., Spriet, I., Wouters, P. J., Vander Perre, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214969 · Cited by 477
Bornstein, S. R., & Chrousos, G. P. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.5.5631 · Cited by 354
Cited by
Metabolomics: beyond biomarkers and towards mechanisms
Johnson, C. H., Ivanisevic, J., & Siuzdak, G. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.25 · Cited by 2,829
Biomarker development in the precision medicine era: lung cancer as a case study
Vargas, A. J., & Harris, C. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.56 · Cited by 556
Self-citationBiomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges
Seijo, L. M., Peled, N., Ajona, D., Boeri, M., Field, J. K., Sozzi, G., Pio, R., Zulueta, J. J., Spira, A., Massion, P. P., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.023 · Cited by 539
NOREVA: normalization and evaluation of MS-based metabolomics data
Li, B., Tang, J., Yang, Q., Li, S., Cui, X., Li, Y., Chen, Y., Xue, W., Li, X., & Zhu, F. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx449 · Cited by 352
Defining the Metabolome: Size, Flux, and Regulation
Zamboni, N., Saghatelian, A., & Patti, G. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.021 · Cited by 300
Metadata
- Authors
- Mathé, E. A., Patterson, A. D., Haznadar, M., Manna, S. K., Krausz, K. W., Bowman, E. D., Shields, P. G., Idle, J. R., Smith, P. B., Anami, K., Kazandjian, D. G., Hatzakis, E., Gonzalez, F. J., & Harris, C. C.
- Venue
- Cancer Research
- Published
- 2014-06-12
- Volume
- 74
- Issue
- 12
- Pages
- 3259-3270
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2113315423
- Cited by
- 195
- References
- 6
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Noninvasive Urinary Metabolomic Profiling Identifies Diagnostic and Prognostic Markers in Lung Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-0109
- The paper
- Mathé, E. A., Patterson, A. D., Haznadar, M., Manna, S. K., Krausz, K. W., Bowman, E. D., Shields, P. G., Idle, J. R., Smith, P. B., Anami, K., Kazandjian, D. G., Hatzakis, E., Gonzalez, F. J., & Harris, C. C. (2014). Noninvasive Urinary Metabolomic Profiling Identifies Diagnostic and Prognostic Markers in Lung Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-0109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.